BOSTON – Panelists at Biopharm America debated strategies for early stage financing as they weighed the importance of a prestigious board, the wisdom of small deals by startups with pharma firms, and the likelihood (or not) that angel investors will help make the case with other backers yet to come.

TAIPEI, Taiwan – Asian capital continues to play a key role in funding biotech development regionally and globally through private investments, M&A deals or IPOs. And 2018 was a particularly exciting one for cross-border investments and health care IPOs, said speakers at the BIO Asia conference. The total deal value of global biopharma IPOs and M&A deals hit a record $49 billion in 2018.

TAIPEI, Taiwan – Western pharma players might not be addressing diseases that are specific to or predominant in Asia, speakers said on the second day of the BIO Asia-Taiwan conference, making regional collaboration important for developing therapeutics targeting unmet needs at home.

TAIPEI, Taiwan – The three-day 2019 BIO Asia-Taiwan Conference and Exhibition opened on Wednesday to discuss how biotechnology could be the next growth engine for Asia. While figures are suggesting Asia is rising as a biotech powerhouse, the region needs to think beyond just capital, talent and patient pool, speakers said.